Bulletin
Investor Alert

press release

Sept. 14, 2020, 7:10 a.m. EDT

Keros Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

LEXINGTON, Mass., Sep 14, 2020 (GLOBE NEWSWIRE via COMTEX) -- LEXINGTON, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") /zigman2/quotes/217766474/composite KROS -0.51% , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Jasbir S. Seehra, Ph.D., President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22 [nd] Annual Global Investment Conference on Monday, September 14, 2020 at 10:30 am ET.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-Beta, or TGF-ss, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros' lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros' third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.

Investor Contact:
Julia Balanova
jbalanova@soleburytrout.com
646-378-2936

COMTEX_371258010/2471/2020-09-14T07:10:08

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2020 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/217766474/composite
US : U.S.: Nasdaq
$ 75.61
-0.39 -0.51%
Volume: 322,619
Nov. 30, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.53 billion
Rev. per Employee
$434,783
loading...

Link to MarketWatch's Slice.